ArticleMolecular pharmacology2022
Differential Enantiomer-Specific Signaling of Cannabidiol at CB
Open access · greenAbstract read
In one paragraph
Article in Molecular pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 10 citations in OpenAlex.
- (+)-Trans-Cannabidiol Is an Agonist at Human CBPharmacology research & perspectives · 2026Article
- Carvone derived cannabidiol enantiomers as novel anticonvulsants.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025Article
- Research and Clinical Practice Involving the Use ofPharmaceuticals (Basel, Switzerland) · 2024Review
- Using In Silico Molecular Docking to Explain Differences in Receptor Binding Behavior of HHC and THCV Isomers: Revealing New Binding Modes.Pharmaceuticals (Basel, Switzerland) · 2024Article
- A collection of cannabinoid-related negative findings from autaptic hippocampal neurons.Scientific reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Taryn Bosquez-BergerGill Center for Biomolecular Science, Department of Psychological and Brain Sciences, Program in Neuroscience, Indiana University, Bloomington, Indiana (T.B., S.W., J.W.M., K.M., A.S.); and Center for Drug Discovery and Department of Pharmaceutical Sciences (C.I.T., S.P.N., A.M.) and Center for Drug Discovery and Department of Chemistry and Chemical Biology (S.J., A.M.), Northeastern University, Boston, Massachusetts.ORCID 0000-0002-0855-9672
Sierra WilsonGill Center for Biomolecular Science, Department of Psychological and Brain Sciences, Program in Neuroscience, Indiana University, Bloomington, Indiana (T.B., S.W., J.W.M., K.M., A.S.); and Center for Drug Discovery and Department of Pharmaceutical Sciences (C.I.T., S.P.N., A.M.) and Center for Drug Discovery and Department of Chemistry and Chemical Biology (S.J., A.M.), Northeastern University, Boston, Massachusetts.
Christos Iliopoulos-TsoutsouvasGill Center for Biomolecular Science, Department of Psychological and Brain Sciences, Program in Neuroscience, Indiana University, Bloomington, Indiana (T.B., S.W., J.W.M., K.M., A.S.); and Center for Drug Discovery and Department of Pharmaceutical Sciences (C.I.T., S.P.N., A.M.) and Center for Drug Discovery and Department of Chemistry and Chemical Biology (S.J., A.M.), Northeastern University, Boston, Massachusetts.
Shan JiangGill Center for Biomolecular Science, Department of Psychological and Brain Sciences, Program in Neuroscience, Indiana University, Bloomington, Indiana (T.B., S.W., J.W.M., K.M., A.S.); and Center for Drug Discovery and Department of Pharmaceutical Sciences (C.I.T., S.P.N., A.M.) and Center for Drug Discovery and Department of Chemistry and Chemical Biology (S.J., A.M.), Northeastern University, Boston, Massachusetts.
Jim Wager-MillerGill Center for Biomolecular Science, Department of Psychological and Brain Sciences, Program in Neuroscience, Indiana University, Bloomington, Indiana (T.B., S.W., J.W.M., K.M., A.S.); and Center for Drug Discovery and Department of Pharmaceutical Sciences (C.I.T., S.P.N., A.M.) and Center for Drug Discovery and Department of Chemistry and Chemical Biology (S.J., A.M.), Northeastern University, Boston, Massachusetts.
Spyros P NikasGill Center for Biomolecular Science, Department of Psychological and Brain Sciences, Program in Neuroscience, Indiana University, Bloomington, Indiana (T.B., S.W., J.W.M., K.M., A.S.); and Center for Drug Discovery and Department of Pharmaceutical Sciences (C.I.T., S.P.N., A.M.) and Center for Drug Discovery and Department of Chemistry and Chemical Biology (S.J., A.M.), Northeastern University, Boston, Massachusetts.
Ken P MackieGill Center for Biomolecular Science, Department of Psychological and Brain Sciences, Program in Neuroscience, Indiana University, Bloomington, Indiana (T.B., S.W., J.W.M., K.M., A.S.); and Center for Drug Discovery and Department of Pharmaceutical Sciences (C.I.T., S.P.N., A.M.) and Center for Drug Discovery and Department of Chemistry and Chemical Biology (S.J., A.M.), Northeastern University, Boston, Massachusetts.
Alexandros MakriyannisGill Center for Biomolecular Science, Department of Psychological and Brain Sciences, Program in Neuroscience, Indiana University, Bloomington, Indiana (T.B., S.W., J.W.M., K.M., A.S.); and Center for Drug Discovery and Department of Pharmaceutical Sciences (C.I.T., S.P.N., A.M.) and Center for Drug Discovery and Department of Chemistry and Chemical Biology (S.J., A.M.), Northeastern University, Boston, Massachusetts straiker@indiana.edu a.makriyannis@northeastern.edu.
Alex StraikerGill Center for Biomolecular Science, Department of Psychological and Brain Sciences, Program in Neuroscience, Indiana University, Bloomington, Indiana (T.B., S.W., J.W.M., K.M., A.S.); and Center for Drug Discovery and Department of Pharmaceutical Sciences (C.I.T., S.P.N., A.M.) and Center for Drug Discovery and Department of Chemistry and Chemical Biology (S.J., A.M.), Northeastern University, Boston, Massachusetts straiker@indiana.edu a.makriyannis@northeastern.edu.
Northeastern University · US
Funding
Project 3 - In vivo pharmacology of cannabinoid receptor probesP01DA009158 · NIDA · UNIVERSITY OF CONNECTICUT STORRS · PI Alexandros Makriyannis · 1994 to 2026
$26.0MStructure and Function of CB2 ReceptorR01DA045020 · NIDA · NORTHEASTERN UNIVERSITY · PI BOHN, LAURA M., KATRITCH, VSEVOLOD · 2017 to 2021
$3.9MINTEGRATIVE PREDOCTORAL TRAINING IN DRUG ABUSE RESEARCH AT INDIANA UNIVERSITYT32DA024628 · NIDA · TRUSTEES OF INDIANA UNIVERSITY · PI Andrea Grace Hohmann, Kenneth Mackie · 2008 to 2026
$3.1MNIDA NIH HHS P01 DA009158NIDA NIH HHS R01 DA045020NIDA NIH HHS T32 DA024628
Abstract
The two main constituents of
Indexed as
CannabidiolCannabinoid Receptor AgonistsDronabinolEndocannabinoidsReceptor, Cannabinoid, CB1Receptor, Cannabinoid, CB2Signal TransductionCannabidiolCannabinoid Receptor AgonistsDronabinolEndocannabinoidsReceptor, Cannabinoid, CB1Receptor, Cannabinoid, CB2
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.